Metrics to compare | ABERA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABERAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.1x | −3.0x | −0.3x | |
PEG Ratio | 0.00 | −0.22 | 0.00 | |
Price/Book | 8.3x | 6.5x | 2.6x | |
Price / LTM Sales | 16.5x | 83.8x | 2.9x | |
Upside (Analyst Target) | - | 157.3% | 64.0% | |
Fair Value Upside | Unlock | 10.3% | 7.8% | Unlock |
Abera Bioscience AB, a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is headquartered in Uppsala, Sweden.